GUIDELINES FOR SYSTEMIC TREATMENT OF PATIENTS WITH PSORIASIS AT THE UNIVERSITY CLINIC FOR DERMATOLOGY – SKOPJE
Keywords:
psoriasis, guidelinesAbstract
Psoriasis is a chronic autoimmune disease that causes inflammation in your skin and encompasses several disease subtypes (plaque, inverse, guttate, pustular, erythrodermic, nail and sebopsoriasis), requiring a standardized approach to diagnosis and treatment. According to current recommendations, the treatment involves the use immunosuppressants and biologic therapy which has already been approved as a first-line treatment for moderate to severe psoriasis in Europe and USA. These guidelines are made for the needs of the University Clinic for Dermatology – Skopje and are based on the European guidelines on the systemic treatment of psoriasis (EuroGuiDerm Guidelines on the systemic treatment of Psoriasis vulgaris, 2020). They include a system for grading disease severity, and recommendations for treatment and monitoring. Systemic treatment modalities included in these guidelines are: acitretin, ciclosporin, methotrexate, adalimumab, apremilast, brodalumab, certolizumab, pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
References
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–98. doi:10.1111/jdv.16915
Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44. doi:10.1159/000250393
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. doi:10.1111/j.1365-2230.1994.tb01167.x
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28(4):438–53. Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(11):1951–63. doi:10.1111/jdv.14390
Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1–70.
Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–90. doi:10.1111/jdv.14014
Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989;69(1):35–40.
Samarasekera EJ, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712. doi:10.1136/bmj.e6712
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–83. doi:10.1111/jdv.15377
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85. doi:10.1016/j.jaad.2009.06.037
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
European Medicines Agency. Cosentyx - Summary of product characteristics (Annex I). 01/04/2016. Cosentyx -EMEA/H/C/003729 -II/0008.2016.
Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. doi:10.1186/s13075-019-1876-6
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700.
Novartis Pharmaceuticals Corporation. Secukinumab (AIN457) - Advisory Committee Briefing Material: Available for Public Release. U.S. Food and Drug Administration. 2014.
